Publicaciones en colaboración con investigadores/as de Institute Catalá Oncología (17)

2019

  1. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer

    Anti-Cancer Drugs, Vol. 30, Núm. 6, pp. 628-635

2018

  1. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study

    Investigational New Drugs, Vol. 36, Núm. 3, pp. 468-475

2016

  1. SEOM Clinical Guideline in ovarian cancer (2016)

    Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1206-1212

2015

  1. Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS)

    Annals of Surgical Oncology, Vol. 22, Núm. 9, pp. 2948-2957

2012

  1. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: A phase II study evaluating co-treatment with dexamethasone

    Investigational New Drugs, Vol. 30, Núm. 2, pp. 729-740

2011

  1. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: A Spanish group for research on sarcomas study

    Journal of Clinical Oncology, Vol. 29, Núm. 18, pp. 2528-2533

  2. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study

    Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 55, Núm. 6, pp. 680-687

2010

  1. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: A Spanish Group for Sarcoma Research (GEIS) Study

    Annals of Oncology, Vol. 21, Núm. 7, pp. 1552-1557

2006

  1. Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: A GEIS study

    British Journal of Cancer, Vol. 94, Núm. 12, pp. 1797-1802

  2. Phase II trial of doxorubicin plus escalated high-dose ifosfamide in patients with advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS)

    Sarcoma, Vol. 2006

2005

  1. Phase II clinical trial with pegylated liposomal doxorubicin (CAELYX®/Doxil®) and quality of life evaluation (EORTC QLQ-C30) in adult patients with advanced soft tissue sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)

    Sarcoma, Vol. 9, Núm. 3-4, pp. 127-132

  2. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: A GEICO (Grupo Español de Investigación en Cáncer de Ovario) study

    Annals of Oncology, Vol. 16, Núm. 5, pp. 749-755

2004

  1. Salvage surgical resection after High-Dose Ifosfamide (HDIF) based regimens in Advanced Soft Tissue Sarcoma (ASTS): A potential positive selection bias - A study of the Spanish group for research on sarcomas (GEIS)

    Journal of Surgical Oncology, Vol. 88, Núm. 1, pp. 44-49

  2. Sequential Dose-Dense Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcomas: A Phase II Trial by the Spanish Group for Research on Sarcomas (GEIS)

    Cancer, Vol. 100, Núm. 7, pp. 1498-1506

2000

  1. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer

    Clinical Cancer Research, Vol. 6, Núm. 6, pp. 2356-2362

1998

  1. Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: A study of the Spanish Group for Research on Sarcomas (GEIS)

    Annals of Oncology, Vol. 9, Núm. 7, pp. 783-785

  2. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS)

    Annals of Oncology, Vol. 9, Núm. 8, pp. 871-876